MIF and cancer: When limiting the analysis to only prostate cancer studies, the heterogeneity decreased substantially to low levels (I2 = 22.7%, p = 0.250) and the association between the C genotype of the Mif promoter polymorphism and cancer was even greater [OR = 3.72 (2.55-5.41), p < 0.0001].